glp 1 and GLP-1 GLP-1 Agonists: A Comprehensive Overview

Mao R, Doyon G, Gordon IO, Li J, Lin S, Wang J, et al

Reduces A1C by approximately 1.0% to 1.5% in monotherapy

The Food and Drug Administration (FDA) has issued specific guidance for sponsors of new drugs to encourage evaluation of potential DDI with COCs [42]

Antibodies targeting IL1- have also shown mixed, although more positive effects, particularly in reducing HbA1c with IL1- antagonism [206], with recent evidence suggesting that combined TNF-alpha and IL1- blockade may be most effective for glycemic control [207]

Keywords: glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, gastric inhibitory peptide, incretins, dual-agonism, type 2 diabetes, obesity 1